Health Economics and HTA and its role in pricing and reimbursement, pipeline and in-lisencing evaluations as well as portfolio and company valuations in the biotech and pharmaceutical sector is ever increasing. While I was searching the web for various news on the topic, I actually couldn't find a blog that offers a platform of exchange among professionals in this field around the various topics - so there we go now and I hope you enjoy the information... Cheers Ulf
1.21.2008
Better differentiation of oncology drugs will be required for market access
Today I came across a timely article from Graham Lewis, VP global strategy at IMS, on oncology drug development and related market acces and funding issues.
No comments:
Post a Comment